title: Alopecia areata during treatment with biologic agents.
authors.forename: Antonella
authors.initials: A
authors.lastname: Tosti
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Pazzaglia
authors.forename: Michela
authors.initials: M
authors.lastname: Starace
authors.forename: Sara
authors.initials: S
authors.lastname: Bellavista
authors.forename: Colombina
authors.initials: C
authors.lastname: Vincenzi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Tonelli
mesh_terms: D000328:Adult; D000506:Alopecia Areata / Q000139:chemically induced* / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002464:Cell Migration Inhibition; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; C472181:efalizumab